tbuckley/cabot-search huggingface dataset:
YM150, An Oral Direct Inhibitor of Factor Xa, Demonstrated a Predictable and Dose-Proportional Pharmacokinetic/Pharmacodynamic Profile After Single and Multiple Dosing: Results From Three Studies
Authors: Dorien Groenendaal– van de Meent, Marten Heeringa, Takeshi Kadokura, Frank Verheggen, Gregory Strabach, Hartmut Heinzerling
Journal: Blood (2010)
Long-term outcome of endoscopic ultrasound-guided pelvic abscess drainage: a two-center series
Authors: Laurent Poincloux, Fabrice Caillol, Christophe Allimant, Erwan Bories, Christian Pesenti, Aurélien Mulliez, Frederic Faure, Olivier Rouquette, Michel Dapoigny, Armando Abergel, Marc Giovannini
Journal: Endoscopy (2017)

<b>Background and study aim</b> Endoscopic ultrasound (EUS)-guided pelvic abscess drainage has been reported but long-term data remain limited. This two-center study evaluated long-term outcome of EUS-guided pelvic abscess drainage. <b>Patients and methods</b> Between May 2003 and December 2015, 37 consecutive patients were treated for perirectal or perisigmoid abscesses via EUS-guided drainage using plastic or lumen-apposing metal stent (LAMS). Clinical success was defined as complete resolution of the abscess on follow-up computed tomography (CT) scan at 4 weeks with symptom relief. Long-term success was defined as abscess resolution without the need for surgery and without recurrence on long-term follow-up (> 12 months). <b>Results</b> Median abscess size was 60 mm (interquartile range 41 – 70). Causes were postsurgical (n = 31, 83.8 %) or secondary to medical conditions (n = 6, 16.2 %). EUS-guided drainage involved needle aspiration (n = 4), plastic stent placement (n = 29) or LAMS placement (n = 4 patients). Technical and clinical success was achieved in 37 patients (100 %; 95 % confidence interval [CI] 91 – 100) and 34 patients (91.9 %; 95 %CI 78 – 98), respectively (5 patients needed a second EUS-guided intervention within 14 days after drainage). One patient required surgery and one required best supportive care owing to persistent abscess. Early complications were perforation requiring surgery (n = 1), stent migration (n = 1), and rectal discomfort (n = 1). At a median follow-up of 64 months (IQR 19 – 81), two patients experienced abscess recurrence, at 3 and 12 months, respectively, and were treated surgically. Long-term success was achieved in 32 of 37 patients (86.5 %; 95 %CI 71 – 95). <b>Conclusion </b>EUS-guided drainage of pelvic abscess is safe, has good long-term outcome, and should be considered as an alternative to percutaneous and surgical drainage.
FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
Authors: A. Falcone, C. Cremolini, F. Loupakis, S. Lonardi, M.E. Casagrande, S. Murgioni, L. Salvatore, G. Masi, V. Fanotto, C. Granetto, F. Marmorino, L. Ginocchi, S. Ziampiri, R. Grande, G. Tonini, S. Delfanti, S. Di Donato, G. Fontanini, L. Boni, V. Zagonel
Journal: Annals of Oncology (2016)
STROKE AND BLEEDING RISK IN PATIENTS WITH ATRIAL FIBRILLATION WITH RESUMPTION OF ORAL ANTICOAGULATION FOLLOWING TRAUMATIC INJURY: A DANISH NATIONWIDE COHORT STUDY
Authors: Laila Staerk, Gunnar Gislason, Gregory Lip, Emil Fosbol, Caroline Sindet-Pedersen, Kasper Gadsbøll, Anders N. Bonde, Ellen Holm, Christian Torp-Pedersen, Jonas Olesen
Journal: Journal of the American College of Cardiology (2016)
Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma
Authors: P. Hwu, O. Hamid, R. Gonzalez, J.R. Infante, M.R. Patel, F.S. Hodi, K.D. Lewis, J. Wallin, G. Mwawasi, E. Cha, N. Richie, M. Ballinger, R. Sullivan
Journal: Annals of Oncology (2016)
Pilot trial of vigil immunotherapy in Ewing’s sarcoma.
Authors: Maurizio Ghisoli, Minal A. Barve, Reva Schneider, Robert Gary Mennel, Carl Lenarsky, Gladice Wallraven, Padmasini Kumar, Derek Nemunaitis, Alyssa Roth, Neil N. Senzer, Frederick A. Fletcher, John J. Nemunaitis
Journal: Journal of Clinical Oncology (2015)

10522 Background: Ewing’s sarcoma is the second most common primary bone malignancy in children and adolescents. While front-line intensive multimodality treatment significantly improves survival in first line treatment, the prognosis for metastatic patients with either disease relapse within two years of initial therapy or initially resistant to chemotherapy is very poor with few long-term survivors and 1-year survival generally less than 20%. Methods: We implemented a Phase I trial of 12 metastatic Ewing’s sarcoma patients who were either multiply recurrent (n = 11) or had failed frontline treatment within 2 years (n = 1). Patients received Vigil (previously called FANG) vaccine dosed between 1x106, 4x106, 1x107 or 2.5x107cells/intradermal injection/month for ≥ 4 months. Vigil is comprised of irradiated autologous tumor transfected with a dual DNA plasmid expressive of GMCSF and bi-shRNA furin components. Knockdown of furin down regulates both downstream TGFβ1 and TGFβ2 expression. Safety and clinical responses were monitored. Patient immune responsiveness to unmodified tumor cells was assessed by sequential IFNγ-ELISPOT assay using whole blood mononuclear samples starting at baseline (pre-treatment) and sequentially after treatment. Results: None of the 12 patients (47 vaccinations) developed Grade 2/3/4 drug related toxicity. Median product release GMCSF expression was 1858 pg/106 cells; median knockdown of TGFβ1 and TGFβ2 was 100% and 99%, respectively. Eight patients have been sequentially assessed for circulating mononuclear cell IFNγ-ELISPOT response, all of whom were IFNγ-ELISPOT negative at baseline. In all eight, follow up IFNγ-ELISPOT at month 1 or month 4 (one patient) post-Vigil converted to positive ( > 10 spots/106cells and > 2x baseline). One patient achieved a partial tumor response (38% tumor reduction, RECIST 1.1). The estimated Kaplan-Meier median survival of these 12 patients at Year 1 was 75%. Conclusions: In this phase 1 study in patients with Ewing’s sarcoma, Vigil immunotherapy was well tolerated, elicited a tumor-specific systemic immune response in all patients, and was associated with favorable 1-year survival. Further clinical testing is warranted. Clinical trial information: NCT01061840.
Do MDR1 &amp; CYP3A5 genetic polymorphisms influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Authors: H. Natarajan, L. Kumar, S. Bakhshi, A. Sharma, M. Kabra, T. Velpandian, A. Gogia, S. Shastri, Y.K. Gupta
Journal: Annals of Oncology (2016)
Clinical next generation sequencing (NGS) of esophagogastric (EG) adenocarcinomas identifies distinct molecular signatures of response to HER2 inhibition, first-line 5FU/platinum and PD1/CTLA4 blockade
Authors: Y.Y. Janjigian, F. Sanchez-Vega, P. Jonsson, Y. Tuvy, N. Bouvier, J. Riches, R. Kundra, G. Ku, J.F. Hechtman, D. Kelsen, L. Tang, D. Ilson, E. Vakiani, Z. Stadler, M. Callahan, D.B. Solit, M.F. Berger, B.S. Taylor, N. Schultz
Journal: Annals of Oncology (2016)
Making uncertainty work
Authors: Sophie Cook
Journal: BMJ (2017)

Vitamin D supplementation is always on the shortlist of clinical topics guaranteed to spark interest and debate. The term “supplement” might conjure up thoughts of an added extra—something beneficial or enhancing—but vitamins are treatments with potential harms and benefits. The plethora of evidence requires careful navigation before embarking on therapy. Bolland and colleagues recently explained the uncertainty surrounding Vitamin D supplementation, concluding that it should not be used in adults to prevent non-musculoskeletal disease (doi:10.1136/bmj.i6201 …
The Transcriptome of Multiple Myeloma (MM) Defines Disease Subgroups with Distinct Genetic and Clinical Features.
Authors: Fenghuang Zhan, Bart Barlogie, Yongsheng Huang, Eric Rasmussen, Jeffrey Sawyer, M. Santra, Ronald Walker, Guido Tricot, John Crowley, Elias Anaissie, John Shaughnessy
Journal: Blood (2004)
P08.39 Characteristics of adults’ gliomas with H3-K27M mutations
Authors: M. Esteban Mader, C. Bonnet, D. Meyronet, M. Joly, E. Uro-Coste, F. Forest, J. Guyotat, A. Jouvet, J. Honnorat, F. Ducray
Journal: Neuro-Oncology (2016)

PURPOSE: Subventricular zone(SVZ)is a paired brain structure situated throughout the lateral walls of the lateral ventricles,a known site of neurogenesis and self-renewing neurons in the adult brain.Some current theories propose that brain tumour stem cells originating from SVZ play a role in progression of high-grade gliomas.Since almost all glioblastomas(GBM) progress locally despite aggressive surgery and radiotherapy,recur within the high-dose irradiation volume in most cases, the theory of tumor cell migration from SVZ is interesting to explore.Irradiation of SVZ supposed to kill brain tumor stem cells which may alter tumor progression and survival.Evaluating the impact of the radiation dose to SVZ on progression rates and overall survival in GBM is our aim.MATERIAL-METHOD: Study population consisted of 80 GBM patients(23f,57m)with a median age of 55.5(21-75)who were treated from January 2012 to December 2014.All patients underwent surgery followed by adjuvant radiotherapy(60Gy/30fractions)and concomitant/adjuvant temozolomid.Bilateral SVZ were contoured on MRI images and registered to planning CT slices.Target volumes and organs at risk were also contoured.Conformal radiotherapy with 3-4fields or IMRT with1-2volumetric arcs were used for planning.Median doses for ipsilateral, contralateral and bilateral SVZ were recorded and relations with progression and survival were analyzed using two threshold values at 40Gy and 50Gy.Analyses were performed after a median follow-up of 13months.RESULTS: Median progression free survival(PFS)was 10 months(2-36) and overall survival(OS) was 12 months(3-48).The unfavorable prognostic factors affecting PFS were tumor extending to ventricles(p50 Gy(p50 Gy(p<0.05).The unfavorable prognostic factors affecting OS were tumor extending to ventricles(p40Gy(p40Gy(p<0.05).In multivariate analysis of prognostic factors, tumor extending to ventricles was the only unfavorable factor for both PFS(p<0.01)andOS(p<0.01).CONCLUSIONS: PFS and OS were shorter in the patients in whom tumor was extending to ventricles and in those where SVZ received at least 40-50 Gy.The data of this study is supports the previous studies showing an inverse correlation between irradiation of SVZ and prognosis.With the present data we can only speculate that those tumors extending deep into the lateral ventricles likely to be larger in size, closer to nearby sensitive structures, and not amenable to total resection.Radiation volumes should cover some parts of SVZ and lateral ventricles to give the prescribed dose to in those unfavorable tumors, which may explain the inverse correlation with SVZ irradiation and survival.Further research is required to clarify the role of brain tumor stem cells locates at SVZ in the prognosis of high-grade gliomas.
The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation
Authors: Michelle Perugini, Saumya E Samaraweera, Anna L Brown, Nik Cummings, Silke Danner, Ing Soo Tiong, Francine E Garrett-Bakelman, Martin P. Carroll, Michael W. Becker, Stephen S. Chung, Christopher Y. Park, Christopher E Mason, Monica L. Guzman, Ross L. Levine, Ari M Melnick, Luen Bik To, Andrew H Wei, Ian D Lewis, Richard J D'Andrea
Journal: Blood (2014)
TMIC-27. CONTACT-INDUCED BI-DIRECTIONAL PRO-SURVIVAL SIGNALING BETWEEN ENDOTHELIAL CELLS AND CANCER STEM-LIKE CELLS IN GLIOBLASTOMA
Authors: Monica Burgett, Amy Nowacki, Justin Lathia, Jeremy Rich, Candece Gladson
Journal: Neuro-Oncology (2016)

We have demonstrated previously that direct contact between brain endothelial cells (ECs) and cancer stem-like cells (CSCs) from glioblastoma (GBM) significantly enhances endothelial cell migration and angiogenesis through a distinct signaling pathway (Burgett et al, Oncotarget 2016; doi: 10.18632/oncotarget.9700). To determine whether this contact promotes bi-directional signaling that regulates survival, we co-cultured ECs with CSCs on laminin in neurobasal media (NBM) without growth factors (3 hrs) and analyzed the mRNA expression of genes regulating survival and apoptosis with comparison to the mRNA levels found for ECs or CSCs cultured in the conditioned media from EC-CSC co-culture on laminin in NBM without growth factors (CM/EC+CSC). ECs or CSCs from co-culture or from culture in CM/EC+CSCs were harvested with accutase, sorted for expression or not of the EC marker CD31, and stained for the EC marker vWf or for the CSC marker Sox2. We found that the direct contact of ECs and CSCs significantly increased the mRNA levels of the anti-apoptotic proteins Bcl2 and survivin by 58- and 5.2-fold, respectively in ECs, compared to the mRNA levels of these genes in ECs cultured in CM/EC+CSCs. We also found that the direct contact of ECs and CSCs significantly increased the mRNA levels of Bcl2 and survivin by 2.3- and 3.5-fold in CSCs as well as significantly decreased the mRNA level of the apoptosis-inducing Fas ligand in CSCs by 3.5-fold, as compared to CSCs cultured in CM/EC+CSC. In contrast, there was no change in the mRNA levels of MCL1 and TRAF1 genes in ECs or CSCs that were in direct contact. These data suggest that direct contact between ECs and CSCs promotes bi-directional pro-survival signaling in the perivascular niche in GBM that is not due to secreted factors from ECs or CSCs.
A Quantitative Multiplex PCR Assay, Validated by a High Resolution Array Comparative Genomic Hybridization Analysis, Provides Information Regarding Genomic Imbalances and Prognosis in Diffuse Large B-Cell Lymphomas.
Authors: Fabrice Jardin, Philippe Ruminy, Francoise Parmentier, Jean-pierre Kerckaert, Vinciane Rainville, Jean Michel Picquenot, Gerard Buchonnet, Dominique Penther, Christian Bastard, Herve Tilly
Journal: Blood (2006)
QLIF-25. PHYSICAL HEALTH RISKS IN NEURO-ONCOLOGY FAMILY CAREGIVERS
Authors: Paula Sherwood, Anna Marsland, Heidi Donovan, Jason Weimer, Terri S. Armstrong, Jan Drappatz
Journal: Neuro-Oncology (2016)

Family caregivers of persons with a primary malignant brain tumor have reported extremely high levels of emotional distress compared to similarly aged adults who do not identify as caregivers or to caregivers of persons with other health conditions. Despite several decades of research linking family caregiver distress to activation of psycho-biological stress pathways, little research has been done in cancer and almost none in neuro-oncology. The purpose of this analysis was to evaluate the relationship between emotional health and levels of C-reactive protein (CRP), a protein that is closely linked to poor cardiovascular health. As part of an ongoing NIH-funded caregiver study (R01-NR013170), 72 caregivers completed measures of anxiety (Profile of Mood States) and depressive symptoms (Center for Epidemiologic Studies-Depression) within two months of patients’ diagnosis. In addition, plasma was collected from caregivers for CRP levels. High throughput chemistry analysis with high sensitivity reagent was utilized to obtain clinical levels of CRP. Linear regression analysis was performed to determine the impact of anxiety and depressive symptoms on caregivers’ CRP levels controlling for age and gender. Caregiver CRP levels ranged from 0.03mg/L to 1.32mg/L; M=0.25mg/L, SD=0.29mg/L (CRP values between 1 and 2.9 indicate intermediate risk for cardiovascular disease). The regression model accounted for 22% of the variance in CRP. Higher CRP levels were associated with both higher levels of depressive symptoms (β=0.02; p=0.09) and higher levels of anxiety (β=0.06, p=0.02). Findings suggest that poor emotional health during caregiving is associated with markers of risk for cardiovascular disease. Clinically, interventions to address emotional health in caregivers should be implemented at the time of diagnosis. Future studies are needed to determine how these relationships change throughout the care situation, particularly given the strong link between CRP and cardiovascular health.
Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.
Authors: Nicolaus Kröger, Tatjana Zabelina, Marion Heinzelmann, Georgia Schilling, Christine Wolschke, Heinrich Lellek, Thomas Stübig, Maite Lestin, Haefaa Alchalby, Francis Ayuk, Djordje Atanackovic, Ulrike Bacher, Boris Fehse, Axel R. Zander
Journal: Blood (2009)
A Novel Class of Sulfonanilides Entering Clinical Trials for Targeted Treatment of Multiple Myeloma: Dual-Mechanism Compounds Inhibiting HIF1A-Signaling and Inducing Apoptosis
Authors: Dirk Hose, Anja Seckinger, Hartmut Goldschmidt, Tobias Meißner, Blanka Leber, Kai Neben, Jens Hillengass, Uta Bertsch, Bernd Janssen, Bernard Klein, Joe Lewis, Karin Vanderkerken, Christoph Schultes
Journal: Blood (2010)
Fecal Calprotectin In Allogeneic Stem Cell Trasplantation as Surrogate Marker of Gastrointestinal Graft Versus Host Disease
Authors: Mariana Bastos Oreiro, Ana Lopez de la Guia, Jose B Nieto, Raquel De Paz, Patricia Baltasar, Dolores Hernandez, Ana Rodriguez de la Rua, David Gallardo, Miguel Canales
Journal: Blood (2010)
Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequentBAP1,PIK3CA, and other actionable genomic alterations
Authors: K. Wang, J.D. McDermott, A.B. Schrock, J.A. Elvin, L. Gay, S.D. Karam, D. Raben, H. Somerset, S.M. Ali, J.S. Ross, D.W. Bowles
Journal: Annals of Oncology (2017)
EPID-04. TUMOR BOARD CONFERENCES IN NEURO-ONCOLOGY: A NATIONWIDE PROVIDER SURVEY
Authors: James Snyder, Lonni Schultz, Tobias Walbert
Journal: Neuro-Oncology (2016)

Tumor board or multidisciplinary cancer meetings (MCM) are the centerpiece of coordinated specialized neuro-oncology care. Little is known on how these meetings are implemented. Benefits of MCM include coordination, direction for complicated cases, education, and a forum for communication, emerging technology, and clinical trials. This study identifies participation and utilization of neuro-oncology MCM with the goal of improving practice patterns and establishing models for high value care. A cross-sectional descriptive internet survey was used. 85 neuro-oncology centers were identified by the Society for Neuro-Oncology and the American Brain Tumor Association. In addition, NCI designated cancer centers, participants in the Adult Brain Tumor Consortium, or the Brain Tumor Trials Collaborative were asked to participate. 46 centers completed the survey. All centers reviewed primary brain tumors, 93% discussed neoplastic spine disease, 89% metastatic brain lesions, 40% paraneoplastic disease. 98% discuss “challenging cases”, 96% recurrent disease, 82% undiagnosed or pre-surgical cases, 89% utilize radiology review. 100% of MCM included Neuro-Oncologists, Neurosurgery, and Radiation Oncology; Radiologist 98%, Pathologist 96%, and clinical trials 64%. Geneticist, Behavioral Health, and Social Work less than 15%. 76% reviewed Pathology. 80% meet weekly, and 36% include satellite centers. Individual preparation time varied 15-300 minutes. 94% value MCM for clinical decision-making, access to clinical trials 69%, and education 89%. Only 13% document MCM in the medical record. 38% of centers use a molecular tumor board, however many commented with uncertainty as to how this is defined. Neuro-oncology MCMs at leading U.S. institutions show high congruity of core disciplines, cases discussed, and perceived value. There is strong agreement on the role of clinical decision making and education, but the implementation of recommendations varies widely. We identified marked variability in preparation time, documentation, and high uncertainty as to the definition and application of a molecular tumor board.
The Heme Scavenger Hemopexin Reverts Heme-Driven Pro-Inflammatory Phenotypic Switching of Macrophages in Sickle Cell Disease
Authors: Francesca Vinchi, Milene Costa da Silva, Giada Ingoglia, Sara Petrillo, Nathan Brinkman, Adrian Zuercher, Adelheid Cerwenka, Emanuela Tolosano, Martina U. Muckenthaler
Journal: Blood (2015)
Physical activity counseling in primary care: Insights from public health and behavioral economics
Authors: Kerem Shuval, Tammy Leonard, Jeffrey Drope, David L. Katz, Alpa V. Patel, Melissa Maitin‐Shepard, On Amir, Amir Grinstein
Journal: CA A Cancer Journal for Clinicians (2017)

Abstract Physical inactivity has reached epidemic proportions in modern society. Abundant evidence points to a causal link between physical inactivity and increased risk for numerous noncommunicable diseases, such as some types of cancer and heart disease, as well as premature mortality. Yet, despite this overwhelming evidence, many individuals do not meet the recommended amount of physical activity required to achieve maximum health benefits. Because primary care physicians’ advice is highly regarded, clinicians have the unique opportunity to play an important role in enabling patients to modify their behavior at the point of care with the goal of guiding patients to adopt and maintain an active lifestyle. In the current study, the authors evaluate pertinent literature from the fields of medicine/public health and economics/psychology to suggest a comprehensive approach to physical activity counseling at the primary care level. They first examine the public health approach to physical activity counseling, and then proceed to offer insights from behavioral economics, an emerging field that combines principles from psychology and economics. The application of key behavioral economics tools (eg, precommitment contracts, framing) to physical activity counseling in primary care is elaborated. CA Cancer J Clin 2017;67:233–244 . © 2017 American Cancer Society .
Clinical significance of thymidine kinase 1 expression on TAS-102 treatment in RECOURSE phase III trial of TAS-102 versus placebo for metastatic colorectal cancer
Authors: K. Yamazaki, T. Yoshino, E. Shinozaki, Y. Komatsu, Y. Tsuji, T. Nishina, H. Baba, T. Denda, N. Sugimoto, A. Tsuji, K. Yamaguchi, T. Takayama, Y. Shimada, Y. Hamamoto, K. Muro, M. Gotoh, T. Tanase, A. Ohtsu
Journal: Annals of Oncology (2016)
Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment: assessment by physician, nurse and patient. Preliminary results from an Italian multicenter survey
Authors: S. Carnio, D. Galetta, V. Scotti, D.L. Cortinovis, A. Antonuzzo, S. Pisconti, A. Rossi, O. Martelli, F.L. Cecere, E. Bria, A. Del Conte, V. Pegoraro, E.S. Montagna, J. Topulli, D. Pelizzoni, S.G. Rapetti, M. Gianetta, S. Novello
Journal: Annals of Oncology (2016)
Safety and efficacy profile of ramucirumab alone or combined with paclitaxel in metastatic gastric cancer (MGC): A real-life overview of compassionate-use named patients (pts) (RAMoss study)
Authors: M. Di Bartolomeo, M. Niger, M.M. Laterza, C. Vivaldi, E. Giommoni, A. Zaniboni, S. Bozzarelli, G. Tomasello, T. Sava, M. Spada, A. Bittoni, S. Galdy, A. Spallanzani, F. Bassan, S. Scagnoli, F. Morano, R. Berenato, M. Caporale, P. Filippo, F. De Vita
Journal: Annals of Oncology (2016)
Enhancement of Imatinib-Induced Apoptosis through Catalase Activity Modulation in Imatinib-Resistant Chronic Myelogenous Leukemia Blastic Phase Cells.
Authors: Jolie Kiemlian Kwee, Ana Carolina dos Santos Ferreira, Diogo Gomes Luque, Flavia da Cunha Vasconcelos, Karina Lani Silva, Claudete Esteves Klumb, Raquel Ciuvalschi Maia
Journal: Blood (2006)
Imatinib Mesylate Induced Cardiotoxicity: a Cardiac Progenitor Cell Disease?.
Authors: Lucia Prezioso, Federica Galaverna, Silvia Tanzi, Caterina Frati, Monia Savi, Costanza Lagrasta, Stefano Cavalli, Serena Galati, Francesca Ferraro, Antonella Deangelis, Elena Piegari, Francesco Rossi, Vittorio Rizzoli, Federico Quaini
Journal: Blood (2009)